Ann S. LaCasce, MD, of Dana-Farber Cancer Institute, discusses results from the CALGB 50801 Alliance study, which showed that a PET scan–adapted approach may reduce the need for radiation treatment and may improve progression-free outcomes in patients with stage I/II bulky classic Hodgkin lymphoma (Abstract 7507).
Thierry André, MD, of Hôpital Saint-Antoine, discusses final overall survival data for the phase III KEYNOTE-177 study, which confirmed pembrolizumab as a new standard of care for first-line treatment of patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract 3500).
Byoung Chul Cho, MD, PhD, of the Yonsei Cancer Center, discusses study results that showed treatment with the EGFR-MET bispecific antibody amivantamab plus the EGFR inhibitor lazertinib yielded responses in 36% of chemotherapy-naive patients with non–small cell lung cancer whose disease progressed on osimertinib. Genetic biomarkers may be able to identify patients most likely to benefit from the combination regimen (Abstract 9006).
Vamsidhar Velcheti, MD, of New York University, discusses overall survival and exploratory subgroup analyses from the phase II CodeBreaK 100 trial, which evaluated the use of sotorasib in pretreated KRAS G12C–mutant non–small cell lung cancer (Abstract 9003).
Ian Chau, MD, of Royal Marsden NHS Foundation Trust, discusses first results of the CheckMate 648 study, which showed that nivolumab plus chemotherapy and nivolumab plus ipilimumab both demonstrated superior overall survival vs chemotherapy alone in patients with advanced esophageal squamous cell carcinoma. These regimens may represent potential new first-line treatment options (Abstract 4001).
